Approval Package for:

APPLICATION NUMBER:  
ANDA 201835

Name: Methylprednisolone Acetate Injectable Suspension, USP (40 mg/1mL and 80 mg/1mL)

Sponsor: Sagent Pharmaceuticals Inc.

Approval Date: June 27, 2018
## Reviews / Information Included in this Review

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Labeling Review(s)</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Pharm/Tox Review</td>
<td></td>
</tr>
<tr>
<td>Bioequivalence Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative &amp; Correspondence Documents</td>
<td></td>
</tr>
</tbody>
</table>
All fields are acceptable.

ANDA 201-835

Methylprednisolone Acetate Injectable Suspension, USP
(40 mg/1mL and 80 mg/1mL)

Sagent Pharmaceuticals Inc.

Rosario D’Costa
Chemistry Division I
Table of Contents

Table of Contents
Chemistry Review Data Sheet
The Executive Summary

I. Recommendations
   A. Recommendation and Conclusion on Approvability
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

II. Summary of Chemistry Assessments
   A. Description of the Drug Product(s) and Drug Substance(s)
   B. Description of How the Drug Product is Intended to be Used
   C. Basis for Approvability or Not-Approval Recommendation

III. Administrative
   A. Reviewer’s Signature
   B. Endorsement Block
   C. CC Block

Chemistry Assessment
Chemistry Comments

None
Chemistry Review Data Sheet

1. ANDA # 201-835

2. REVIEW #: 3A

3. REVIEW DATE: 01/05/18/06/13/18

4. REVIEWER: Rosario D’Costa

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>July 29, 2016</td>
</tr>
<tr>
<td>Amendment:</td>
<td>December 13, 2011</td>
</tr>
<tr>
<td>Amendment:</td>
<td>October 07, 2010</td>
</tr>
<tr>
<td>Original (Application received)</td>
<td>August 13, 2010</td>
</tr>
<tr>
<td>Acceptable for Filing:</td>
<td>August 16, 2010</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>April 18, 2018</td>
</tr>
<tr>
<td>Amendment</td>
<td>March 29, 2018</td>
</tr>
<tr>
<td>Amendment:</td>
<td>December 14, 2017</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Sagent Pharmaceuticals Inc.
Address: 1901 N. Roselle Road, Suite 700
Achaumburg, IL 60195
Representative: Kalpesh Shroff
8. DRUG PRODUCT NAME/CODE/TYPE: Methylprednisolone Acetate Injectable Suspension, USP

9. LEGAL BASIS FOR SUBMISSION: FFD & CA
   The basis for proposed ANDA for Methylprednisolone Acetate Injectable Suspension, USP 40mg/mL and 80mg/mL is the approved reference listed drug, Depo-Medrol®, held by Pharmacia & Upjohn (Pfizer) and the subject of NDA #011757 approved prior to January 01, 1982.

   Paragraph II Certification: Sagent hereby certifies that in its opinion and to the best of its knowledge there are no listed patents in the current edition of Orange Book concerning Methylprednisolone Acetate Injectable Suspension, USP that claim the listed drug referred to in this application or that claim a use of this listed drug. This certification is made in accordance with Section 505 (j) (2) (A) (vii) (II) of the FFD & CA and pursuant to 21 CFR 314.94 (a)(12)(i)(A)(2).
   There is no unexpired exclusivity for the reference listed drug.

10. PHARMACOL. CATEGORY: Anti-Inflammatory

11. DOSAGE FORM: Injectable Suspension

12. STRENGTH/POTENCY: 40mg/mL and 80mg/mL

13. ROUTE OF ADMINISTRATION: Intramuscular

14. Rx/OTC DISPENSED: _X_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   ____SPOTS product – Form Completed
   _X___Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

What are the nomenclature, molecular structure, molecular formula, and molecular weight?

Generic Name: Methylprednisolone Acetate
Chemical Name: Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-(6α,11β) OR 11β, 17, 21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21 acetate OR 11β, 17-Dihydroxy-6α-methyl-3,20-dioxopregna-1,4-dien-21-ylacetate
Molecular Formula: C24H32O6
Molecular weight: 416.51
CAS registry number(s): 53-36-1
Anti-inflammatory

17. RELATED/SUPPORTING DOCUMENTS: None

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td></td>
<td></td>
<td>(0) (16)</td>
<td>3</td>
<td>* Adequate</td>
<td>06/12/18</td>
<td>Y. Peng</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td>(0) (16)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td>(0) (16)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.A. = Not Available; * Adequate with a comment

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
CHEMISTRY REVIEW

Chemistry Review Data Sheet

3 - Reviewed previously and no revision since last review
4 - Sufficient information in application
5 - Authority to reference not granted
6 - DMF not available
7 - Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents: None

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS: CMC Approvable

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>Acceptable</td>
<td>04/04/18</td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>05/11/18</td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Acceptable</td>
<td>06/02/18</td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Acceptable</td>
<td>04/02/18</td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Categorical Exclusion Requested (Acceptable)</td>
<td>02/28/11</td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt. _X_ Yes _ _No If no, explain reason(s) below:
The Chemistry Review for ANDA 201-835

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability
   The chemistry section is adequate in areas of manufacturing and controls and is therefore recommended for “approvable”.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
   N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)
   The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. The drug substance and its impurities are characterized using the standard analytical techniques of FT-IR, $^1$H, $^{13}$C NMR, MS, etc.

   The drug product Methylprednisolone Acetate Injectable Suspension, USP 40mg/mL and 80mg/mL contains Methylprednisolone Acetate as an active ingredient and is based on the reference listed drug Depo-Medrol®. The pH of the drug product injectable suspension is between 3.5 and 7.0. It is used as an anti-inflammatory drug. The Methylprednisolone Acetate Injectable Suspension USP is available in multi-dose glass vials (40mg/1mL filled in 5mL and 10mL glass vials and 80mg/1mL in 5mL glass vials) as a sterile suspension for intramuscular administration.

B. Description of How the Drug Product is Intended to be Used
   The recommended dose for adults is up to 120mg or as prescribed by the physician.

C. Basis for Approvability or Not-Approval Recommendation
   The “approvable” recommendation is based on adequate chemistry and manufacturing controls.
   Labeling is acceptable.
   Bioequivalence is acceptable.
   Microbiology is acceptable.
   EER is acceptable.
Chemistry Assessment

What are the physicochemical properties including physical description, pKa, polymorphism, aqueous solubility (as function of pH), hygroscopicity, melting points, and partition coefficient?

Physicochemical Properties:

The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. It exists in polymorphic forms [4]. The form used by the applicant shows the same pattern as the USP reference standard LG-2. The physicochemical characteristics such as melting point (205° to 208°C), aqueous solubility as a function of pH (mass solubility = 0.015g/L at pH 1 to 9), pKa = 12.41 ± 0.70 and partition co-efficient (Log P = 2.792 ± 0.584 @ 25°C; calculated using [4]) were included in the Amendment dated December 11, 2011.

2.3.5.2 Manufacturer

Who manufactures the drug substance?

[Blank space]

How do the manufacturing processes and controls ensure consistent production of the drug substance?

The complete manufacturing process is described in DMF [4]. Please refer to the DMF for a description of the drug substance manufacturing process, control of materials, in-process controls leading to the drug substance, etc.

Reviewer’s Comments: [Blank space]


Deficiency: The DMF [4] for Methylprednisolone Acetate has been reviewed and found to be inadequate. The DMF holder, [Blank space], has been notified of any deficiencies. The Agency will work with the DMF holder to resolve any issues if the DMF...
holder responses in a timely manner. Please be aware that the quality review of the
sANDA cannot be fully completed until all DMF deficiencies are adequately resolved.
Please consult with your DMF holder and provide the updated relevant drug substance
sections (e.g., impurities, method validation/verification) for further Agency’s evaluation.
The Drug Master File was reviewed and found to be adequate.

The information was extracted from the Drug Master File which was reviewed and found to be adequate with a comment. Also, please refer to Amendments dated April 18, 2018 and March 29, 2018. The response is acceptable.

2.3.5.3 Characterization

How was the drug substance structure elucidated and characterized?

Proof of Structure

Please refer to DMF No for information regarding the Methylprednisolone structure,
based upon spectroscopy and analytical testing.

How were the possible impurities identified and characterized?
Reviewer’s Comments: The firm provided the required information on the physical and chemical properties of the drug substance. For additional information, please refer to the Drug Master File which is current as of June 12, 2018.

2.3.5.4 Control of Drug Substance

What is the drug substance specification? Does it include all the critical drug substance attributes that affect the manufacturing and quality of the drug product?

The active ingredient sterile Methylprednisolone Acetate, USP is fully characterized in accordance with the current USP monograph requirements.
CHEMISTRY REVIEW

The test results meet the acceptance criteria.

Reviewer’s Comments: The drug substance is adequately characterized per the proposed tests and specifications.

Analytical Procedures:

For each test in the specification, is the analytical method(s) suitable for its intended use and, if necessary, validated? What is the justification for the acceptance criterion?

The analytical methods (USP) utilized for determination of Methylprednisolone Acetate and impurities in the drug substance were reviewed and found to be suitable for their intended purposes. Please refer to Reviews #1 and 2 for validation data. The drug substance is a compendia item and justification for the acceptance criteria is based on the current USP monograph requirements.

Reviewer’s Comments: The analytical methods (USP) utilized for determination of Methylprednisolone Acetate and impurities in the drug substance were reviewed and found to be suitable for their intended purposes.

2.3.S.5 Reference Standards and Materials

How were the primary reference standards certified?

A reference standard is available from USP. A working standard was prepared by analyzing a batch sample and qualifying it against a reference standard obtained from USP (Section 2.3.S.5; See also DMF (0344).

2.3.S.6 Container Closure System

What container closure system is used for packaging and storage of the drug substance?

For information regarding the container/closure system please refer to DMF (0344).

2.3.S.7 Stability

What drug substance stability studies support the retest or expiration date and storage conditions for the drug substance?
CHEMISTRY REVIEW

Please refer to DMF for a description of the drug substance stability program, study reports and conclusion.

Reviewer’s Comments: For Methylprednisolone Acetate, the firm provided sufficient information on the manufacture, identification and characterization, packaging and stability of the drug substance. For more information, please refer to the Drug Master File.

2.3.P DRUG PRODUCT
2.3.P.1 Description and Composition of the Drug Product

What are the components and composition of the final product? What is the function(s) of each excipient?

The finished drug product, Methylprednisolone Acetate Injectable Suspension, USP (40mg/mL and 80mg/mL) is an off-white colored sterile aqueous suspension for intramuscular administration.

The list of ingredients, their pharmaceutical functions and amount per unit basis are presented in the following table:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Methyprednisolone Acetate Injectable Suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Methylprednisolone Acetate, USP (active)</td>
<td>40.00</td>
</tr>
<tr>
<td>Polyethylene Glycol 3350, NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Polysorbate 80 NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Sodium chloride, USP</td>
<td>0.4</td>
</tr>
<tr>
<td>Monobasic sodium phosphate, NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Dibasic sodium phosphate, NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Benzy alcohol, NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Sodium hydroxide, NF</td>
<td>0.4</td>
</tr>
<tr>
<td>Hydrochloric acid</td>
<td>0.4</td>
</tr>
</tbody>
</table>

* Based on 100% assay.

Do any excipients exceed the IIG limit for this route of administration?

No.

Do the differences between this formulation and the RLD present potential concerns with respect to therapeutic equivalence?

No. The proposed generic formulation and the RLD contain the standard excipients consistent with the design of the parenteral dosage form. It has the same excipients as the innovator’s product.

A comparison of the ingredients in the two formulations is presented in the following table:
Therefore, there are no potential concerns with respect to therapeutic equivalence as the two formulations are similar.

2.3.P.2 Pharmaceutical Development

The basis of Sagent Pharmaceuticals Inc. proposed abbreviated new drug application [ANDA] for Methylprednisolone Acetate Injectable Suspension, USP (Multi-dose vials) is the approved reference listed drug [RLD] Depo-Medrol® (Methylprednisolone Acetate Injectable Suspension, USP). The generic drug product should contain the same ingredients, be sterile and pharmaceutically equivalent to the reference listed drug.

2.3.P.2.1 Components of the Drug Product

2.3.P.2.1.1 Drug Substance

Which properties or physical chemical characteristics of the drug substance affect drug product development, manufacture, or performance?

2.3.P.2.1.2 Excipients
What evidence supports compatibility between the excipients and the drug substance?

The drug product Methylprednisolone Acetate Injectable Suspension, USP contains the same excipients as that in the RLD. The firm conducted compatibility studies between the drug substance and the excipients for 6 weeks during the product development. The presented data shows the API to be compatible with the excipients used in the drug product formulation.

2.3.P.2.2 Drug Product
2.3.P.8.2 Stability Studies Supporting Proposed Shelf Life and Storage Conditions

What drug product stability studies support the proposed shelf life and storage conditions?

For stability studies, the drug product samples were stored under accelerated and controlled room temperature stability conditions (Table). The samples were stored in inverted and upright positions.

<table>
<thead>
<tr>
<th>Batch Strength &amp; Lot Number</th>
<th>Accelerated Stability and Test Intervals</th>
<th>Room Temperature and Test Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>40mg/mL; 7002910 (5mL vial); 7002909 (10mL vial)</td>
<td>40°C ± 2°C/75% ± 5%RH; 0, 1, 2 and 3 months</td>
<td>25°C ± 2°C/60% ± 5%RH; 0, 3, 6, 9, 12, 18, 24 and 36 months</td>
</tr>
<tr>
<td>80mg/mL; 7002912 (5mL vial)</td>
<td>40°C ± 2°C/75% ± 5%RH; 0, 1, 2 and 3 months</td>
<td>25°C ± 2°C/60% ± 5%RH; 0, 3, 6, 9, 12, 18, 24 and 36 months</td>
</tr>
</tbody>
</table>

The firm provided 24 months controlled room temperature stability data for the drug product packaged in the proposed container/closure system. The presented test data meets the acceptance criteria.

Reviewer’s Comments: The stability data for the finished drug product meets the acceptance criteria.

What is the post-approval stability protocol?
In the post-approval stability protocol, the firm commits to place the first three commercial production batches of Methylprednisolone Acetate Injectable Suspension, USP in the marketed container/closure system on stability (25°C ± 2°C/60% ± 5% RH) and tested at intervals of 0, 3, 6, 9, 12, 18, 24 months and 36 months until the desired expiration date is reached. Yearly thereafter, a minimum of one production lot in the marketed container/closure system will be added to the long-term stability program. The stability results will be reported to the Agency in the annual report. Furthermore, the firm commits that if any commercial production lot that fails to meet the acceptance criteria of stability specifications or falls out of specifications, the Agency shall be informed and appropriate actions shall be taken as deemed necessary including product recall where applicable. Any significant chemical, physical, or other deterioration which results in the distributed product acquiring non-compliant characteristics will be reported to FDA as a "Field Alert Report" [21 CFR 314.81]. For additional information regarding the post-approval stability protocol refer to Module 3.2.8.2.

III. Administrative

A. Reviewer's Signature

B. Endorsement Block
Chemist Name/Date: RD’Costa, Ph.D./01/05/18/06/13/18
Chemistry TeamLeader Name/Date: Paul Schwartz, Ph.D.
ProjectManagerName/Date: Gbenga Okubadejo, PM /
M:\MyDocuments\201835.REV03A.doc

Chemistry Review: CMC Approvable

C. CC Block
ANDA
ANDA DUP
DIV FILE
Field Copy
Recommendation:
ANDA: Not Approvable

ANDA 201835-ORIG-1-AMEND-14

Amendment Review

<table>
<thead>
<tr>
<th>Drug Name/Dosage Form</th>
<th>Methylprednisolone Acetate Injectable Suspension, USP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength</td>
<td>40 mg/mL and 80 mg/mL</td>
</tr>
<tr>
<td>Reviewer(s)</td>
<td>Neeraj Chopra</td>
</tr>
<tr>
<td>Applicant</td>
<td>Sagent Pharmaceuticals, Inc.</td>
</tr>
</tbody>
</table>

SUBMISSION(S) REVIEWED DOCUMENT DATE

Quality Response 12/14/2017

DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Type II</td>
<td></td>
<td></td>
<td>1</td>
<td>3/7/2018 by Yuefeng (Simon) Peng</td>
<td>Inadequate</td>
</tr>
</tbody>
</table>

1 Adequate, Adequate with Information Request, Deficient, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

The ANDA submission was last reviewed by Rosario D’Costa, dated 5/18/2017 and found inadequate due to the inadequate DMF.
In response to the complete response letter dated 6/5/2017, applicant submitted the DMF response and risk assessment report for the elemental impurities as per ICH Q3D.
Recent review of the DMF for the drug substance, Methylprednisolone Acetate, by Yuefeng (Simon) Peng dated 3/7/2018 is found to be inadequate.
As requested by the Agency applicant performed the risk assessment of the elemental impurities as per ICH Q3D on the drug substance,
Not Approvable – Major Deficiency

ANDA 201-835

Methylprednisolone Acetate Injectable Suspension, USP
(40 mg/1mL and 80 mg/1mL)

Sagent Pharmaceuticals Inc.

Rosario D’Costa
Chemistry Division I
Table of Contents

Table of Contents ................................................................. 2
Chemistry Review Data Sheet .................................................. 3
The Executive Summary .......................................................... 7

I. Recommendations ............................................................. 7
   A. Recommendation and Conclusion on Approvability .............. 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .... 7

II. Summary of Chemistry Assessments .................................... 7
    A. Description of the Drug Product(s) and Drug Substance(s) ... 7
    B. Description of How the Drug Product is Intended to be Used . 7
    C. Basis for Approvability or Not-Approval Recommendation ... 7

III. Administrative .................................................................... 35
    A. Reviewer’s Signature ....................................................
    B. Endorsement Block ....................................................
    C. CC Block ....................................................................

Chemistry Assessment ............................................................ 7

Chemistry Comments ............................................................ 36
Chemistry Review Data Sheet

1. ANDA # 201-835

2. REVIEW #: 2

3. REVIEW DATE: 02/11/14

4. REVIEWER: Rosario D’Costa

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>October 07, 2010</td>
</tr>
<tr>
<td>Original (Application received)</td>
<td>August 13, 2010</td>
</tr>
<tr>
<td>Acceptable for Filing</td>
<td>August 16, 2010</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>December 13, 2011</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Sagent Pharmaceuticals Inc.
Address: 1901 N. Roselle Road, Suite 700
Achaumburg, IL 60195
Representative: Kalpesh Shroff
Telephone: [Redacted]
Facsimile: 847 908-1601
8. DRUG PRODUCT NAME/CODE/TYPEx: Methylprednisolone Acetate Injectable Suspension, USP

9. LEGAL BASIS FOR SUBMISSION: FFD & CA
   The basis for proposed ANDA for Methylprednisolone Acetate Injectable Suspension, USP 40mg/1mL and 80mg/1mL is the approved reference listed drug, Depo-Medrol®, held by Pharmacia & Upjohn (Pfizer) and the subject of NDA #011757 approved prior to January 01, 1982.
   Paragraph II Certification: Sagent hereby certifies that in its opinion and to the best of its knowledge there are no listed patents in the current edition of Orange Book concerning Methylprednisolone Acetate Injectable Suspension, USP that claim the listed drug referred to in this application or that claim a use of this listed drug.
   This certification is made in accordance with Section 505 (j) (2) (A) (vii) (II) of the FFD & CA and pursuant to 21 CFR 314.94 (a)(12)(i)(A)(2).
   There is no unexpired exclusivity for the reference listed drug.

10. PHARMACOL. CATEGORY: Ant-Inflammatory.

11. DOSAGE FORM: Injectable Suspension

12. STRENGTH/POTENCY: 40mg/mL and 80mg/mL

13. ROUTE OF ADMINISTRATION: Intramuscular

14. Rx/OTC DISPENSED: _x_ Rx ___ OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____ SPOTS product – Form Completed
   ___X___ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

What are the nomenclature, molecular structure, molecular formula, and molecular weight?

Generic Name: Methylprednisolone Acetate
Chemical Name: Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-(6α,11β) OR 11β, 17, 21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21 acetate OR 11β, 17-Dihydroxy-6α-methyl-3,20-dioxopregna-1,4-dien-21-ylacetate
Molecular Formula: C24H32O6
Molecular weight: 416.51
CAS registry number(s): 53-36-1
Anti-inflammatory

17. RELATED/SUPPORTING DOCUMENTS: None

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)(4)</td>
<td>II</td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>02/11/14</td>
<td>Bhattacharya, Nandini</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
CHEMISTRY REVIEW

Chemistry Review Data Sheet

3 - Reviewed previously and no revision since last review
4 - Sufficient information in application
5 - Authority to reference not granted
6 - DMF not available
7 - Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents: None

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS: CMC not Approvable

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>Acceptable</td>
<td>02/11/14</td>
<td>Bhattacharya, Nandini</td>
</tr>
<tr>
<td>EES</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Acceptable</td>
<td>12/11/13</td>
<td>Liu, Theresa</td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Acceptable</td>
<td>08/06/13</td>
<td>Babaa, Nabeel</td>
</tr>
<tr>
<td>EA</td>
<td>Categorical Exclusion Requested (Acceptable)</td>
<td>02/28/11</td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt. _X_ Yes ___ No If no, explain reason(s) below:
The Chemistry Review for ANDA 201-835

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability
The chemistry section is inadequate in areas of manufacturing and controls and is therefore recommended for “non-approvable”.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. The drug substance and its impurities are characterized using the standard analytical techniques of FT-IR, $^1H$, $^{13}C$ NMR, MS, etc.

The drug product Methylprednisolone Acetate Injectable Suspension, USP 40mg/mL and 80mg/mL contains Methylprednisolone Acetate as an active ingredient and is based on the reference listed drug Depo-Medrol®. The pH of the drug product injectable suspension is between 3.5 and 7.0. It is used as an anti-inflammatory drug. The Methylprednisolone Acetate Injectable Suspension USP is available in multi-dose glass vials (40mg/1mL filled in 5mL and 10mL glass vials and 80mg/1mL in 5mL glass vials) as a sterile suspension for intramuscular administration.

B. Description of How the Drug Product is Intended to be Used
The recommended dose for adults is up to 120mg or as prescribed by the physician.

C. Basis for Approvability or Not-Approval Recommendation

The “non-approvable” recommendation is based on inadequate chemistry and manufacturing controls.
Labeling is acceptable.
Bioequivalence is acceptable.
Microbiology is acceptable.
EER is acceptable (Overall recommendation is pending).
Chemistry Assessment

What are the physicochemical properties including physical description, pKa, polymorphism, aqueous solubility (as function of pH), hygroscopicity, melting points, and partition coefficient?

Physicochemical Properties:

The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. It exists in polymorphic forms [b] (4) [b] (4) [b] (4) [b] (4) [b] (4) [b] (4) [b] (4) [b] (4). The form used by the applicant shows the same pattern as the USP reference standard LG-2.

Deficiency: For the drug substance, the physicochemical characteristics such as melting point, aqueous solubility as a function of pH, partition co-efficient, etc. is missing from the document. Please address.

As requested, the firm provided the physicochemical characteristics such as melting point (205°C to 208°C), aqueous solubility as a function of pH (mass solubility = 0.015g/L at pH 1 to 9), pKa = 12.41 ± 0.70 and partition co-efficient (Log P = 2.792 ± 0.584 @ 25°C), etc. which was missing from the document. The response is adequate.

2.3.S.2 Manufacturer

Who manufactures the drug substance?

How do the manufacturing processes and controls ensure consistent production of the drug substance?

The complete manufacturing process is described in DMF [b] (4). Please refer to the DMF for a description of the drug substance manufacturing process, control of materials, in-process controls leading to the drug substance, etc.
2.3.S.3 Characterization

How was the drug substance structure elucidated and characterized?

Proof of Structure

Please refer to DMF No. (b) [4] for information regarding the Methylprednisolone structure, based upon spectroscopy and analytical testing.

2.3.S.4 Control of Drug Substance

What is the drug substance specification? Does it include all the critical drug substance attributes that affect the manufacturing and quality of the drug product?

The active ingredient sterile Methylprednisolone Acetate, USP is fully characterized in accordance with the current USP monograph requirements. All the critical drug substance attributes that affect the manufacture and quality of the drug product such as identification, assay, purity, etc. are included in the drug substance specifications.
III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

Chemist Name/Date: RD’Costa, Ph.D./02/19/14
ChemistryTeamLeaderName/Date: ZSun for TL/02/19/14
ProjectManagerName/Date: Mark Gonitzke, PM, /5/27/2014
M:\MyDocuments\201835.REV02.doc

C. CC Block
ANDA
ANDA DUP
DIV FILE
Field Copy
ANDA: 201-835  APPLICANT: Sagent Pharmaceuticals Inc.

DRUG PRODUCT: Methylprednisolone Acetate Injectable Suspension, USP 40 mg/mL and 80 mg/mL

The following deficiencies listed below may be delivered via the easily correctable deficiency method (10 day firm response expected) if the situation allows □ YES ☒ NO

A. The deficiencies presented below represent MAJOR deficiencies:

1.

2.

3.

4.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comment in your response:

The firms referenced in your ANDA relative to the manufacturing and testing of the drug substance and the product must be in compliance with the cGMP’s at the time of approval.

Sincerely yours,

{See appended electronic signature page}

Robert Iser
Director
Division of Chemistry IV
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROSARIO D COSTA
06/02/2014

MARK A GONITZKE
06/02/2014

ZHIGANG SUN
06/02/2014

NAIQI YA on behalf of ROBERT L ISER
06/10/2014

Reference ID: 3516537
ANDA 201-835

Methylprednisolone Acetate Injectable Suspension, USP
(40 mg/1mL and 80 mg/1mL)

Sagent Pharmaceuticals Inc.

Rosario D’Costa
Chemistry Division I
Table of Contents

Table of Contents ......................................................... 2

Chemistry Review Data Sheet ......................................... 3

The Executive Summary .................................................. 7

I. Recommendations ..................................................... 7
   A. Recommendation and Conclusion on Approvability ...... 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ................................................. 7

II. Summary of Chemistry Assessments ............................. 7
   A. Description of the Drug Product(s) and Drug Substance(s) ......................................................... 7
   B. Description of How the Drug Product is Intended to be Used ......................................................... 7
   C. Basis for Approvability or Not-Approval Recommendation ......................................................... 7

III. Administrative .......................................................... 33
   A. Reviewer’s Signature ..............................................
   B. Endorsement Block ..............................................
   C. CC Block ............................................................

Chemistry Assessment ..................................................... 8
Chemistry Review Data Sheet

1. ANDA # 201-835

2. REVIEW #: 1

3. REVIEW DATE: 02/23/11

4. REVIEWER: Rosario D’Costa

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment:</td>
<td>October 07, 2010</td>
</tr>
<tr>
<td>Original (Application received)</td>
<td>August 13, 2010</td>
</tr>
<tr>
<td>Acceptable for Filing:</td>
<td>August 16, 2010</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

   Name: Sagent Pharmaceuticals Inc.
   Address: 1901 N. Roselle Road, Suite 700
             Achaumburg, IL 60195
   Representative: Kalpesh Shroff
8. DRUG PRODUCT NAME/CODE/TYPE: Methylprednisolone Acetate Injectable Suspension, USP

9. LEGAL BASIS FOR SUBMISSION: FFD & CA
   The basis for proposed ANDA for Methylprednisolone Acetate Injectable Suspension, USP 40mg/mL and 80mg/mL is the approved reference listed drug, Depomedrol®, held by Pharmacia & Upjohn (Pfizer) and the subject of NDA #011757 approved prior to January 01, 1982.

   Paragraph II Certification: Sagent hereby certifies that in its opinion and to the best of its knowledge there are no listed patents in the current edition of Orange Book concerning Methylprednisolone Acetate Injectable Suspension, USP that claim the listed drug referred to in this application or that claim a use of this listed drug.

   This certification is made in accordance with Section 505 (j) (2) (A) (vii) (II) of the FFD & CA and pursuant to 21 CFR 314.94 (a)(12)(i)(A)(2).

   There is no unexpired exclusivity for the reference listed drug.

10. PHARMACOL. CATEGORY: Ant-Inflammatory.

11. DOSAGE FORM: Injectable Suspension

12. STRENGTH/POTENCY: 40mg/mL and 80mg/mL

13. ROUTE OF ADMINISTRATION: Intramuscular

14. Rx/OTC DISPENSED: _X_Rx   ____OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   _X___Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

What are the nomenclature, molecular structure, molecular formula, and molecular weight?

Generic Name: Methylprednisolone Acetate
Chemical Name: Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-(6α,11β) OR 11β, 17, 21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21 acetate OR 11β, 17-Dihydroxy-6α-methyl-3,20-dioxopregna-1,4-dien-21-ylacetate
Molecular Formula: C$_{24}$H$_{32}$O$_{6}$
Molecular weight: 416.51
CAS registry number(s): 53-36-1
Anti-inflammatory

17. RELATED/SUPPORTING DOCUMENTS: None

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE$^1$</th>
<th>STATUS$^2$</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Inadequate</td>
<td>04/11/11</td>
<td>RD'Costa</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^1$ Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
CheMISTRY REVIEW

Chemistry Review Data Sheet

3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents: None

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS: Not Approvable

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td>Deficiency</td>
<td>04/08/11</td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Categorical Exclusion</td>
<td>02/28/11</td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW

The application submission(s) covered by this review was taken in the date order of receipt.  __X__ Yes  ____ No  If no, explain reason(s) below:
The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability
   The chemistry section is inadequate in areas of manufacturing and controls and is therefore recommended for “non-approvable”.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
   N/A

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)
   The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. The drug substance and its impurities are characterized using the standard analytical techniques of FT-IR, $^{1}$H, $^{13}$C NMR, MS, etc.

   The drug product Methylprednisolone Acetate Injectable Suspension, USP 40mg/mL and 80mg/mL contains Methylprednisolone Acetate as an active ingredient and is based on the reference listed drug Depo-Medrol®. The pH of the drug product injectable suspension is between 3.5 and 7.0. It is used as an anti-inflammatory drug. The Methylprednisolone Acetate Injectable Suspension USP is available in multi-dose glass vials (40mg/1mL filled in 5mL and 10mL glass vials and 80mg/1mL in 5mL glass vials) as a sterile suspension for intramuscular administration.

B. Description of How the Drug Product is Intended to be Used
   The recommended dose for adults is up to 120mg or as prescribed by the physician.

C. Basis for Approvability or Not-Approval Recommendation
   The “non-approvable” recommendation is based on inadequate chemistry and manufacturing controls.
   Labeling; Microbiology and EER are pending.
Chemistry Assessment

What are the physicochemical properties including physical description, pKa, polymorphism, aqueous solubility (as function of pH), hygroscopicity, melting points, and partition coefficient?

Physicochemical Properties:

The drug substance Methylprednisolone Acetate sterile is a white or almost white crystalline powder, practically insoluble in water, sparingly soluble in acetone and in alcohol and slightly soluble in ether. It exists in polymorphic forms. The form used by the applicant shows the same pattern as the USP reference standard LG-2.

Deficiency: For the drug substance, the physicochemical characteristics such as melting point, aqueous solubility as a function of pH, partition co-efficient, etc. is missing from the document. Please address.

2.3.S.2 Manufacturer

Who manufactures the drug substance?

The complete manufacturing process is described in DMF. Please refer to the DMF for a description of the drug substance manufacturing process, control of materials, in-process controls leading to the drug substance, etc.
2.3.S.3 Characterization

How was the drug substance structure elucidated and characterized?

Proof of Structure

Please refer to DMF No. [redacted] for full details regarding proof of the Methylprednisolone structure, based upon spectroscopy and analytical testing.

How were the possible impurities identified and characterized?

Deficiency: The Drug Master File # [redacted] was reviewed and found to be inadequate. Please do not respond until the DMF holder has responded to the deficiencies cited in the review.

2.3.S.4 Control of Drug Substance

What is the drug substance specification? Does it include all the critical drug substance attributes that affect the manufacturing and quality of the drug product?
2.3.P.8.2 Stability Studies Supporting Proposed Shelf Life and Storage Conditions

What drug product stability studies support the proposed shelf life and storage conditions?

For stability studies, the drug product samples were stored under accelerated and controlled room temperature stability conditions (Table). The samples were stored in inverted and upright conditions.

<table>
<thead>
<tr>
<th>Batch Strength &amp; Lot Number</th>
<th>Accelerated Stability and Test Intervals</th>
<th>Room Temperature and Test Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>40mg/mL; 7002910 (5mL vial); 7002909 (10mL vial)</td>
<td>40°C ± 2°C/75% ± 5%RH; 0, 1, 2 and 3 months</td>
<td>25°C ± 2°C/60% ± 5%RH; 0, 3, 6, 9, 12, 18, 24 and 36 months</td>
</tr>
<tr>
<td>80mg/mL; 7002912 (5mL vial)</td>
<td>40°C ± 2°C/75% ± 5%RH; 0, 1, 2 and 3 months</td>
<td>25°C ± 2°C/60% ± 5%RH; 0, 3, 6, 9, 12, 18, 24 and 36 months</td>
</tr>
</tbody>
</table>

The firm provided 3 months stability data for the drug product samples stored under accelerated and 12 months under stability data under controlled room temperature stability conditions. The presented stability data meets the proposed acceptance criteria. The analysis of the stability samples shows the minimum as the test results fall below the proposed specifications. Based on the satisfactory accelerated stability data (3 months), a tentative 24 months expiration dating period is proposed, which will be confirmed by long term temperature stability data. This is acceptable to the Agency.

Reviewer’s Comments: The test results for stability of the finished drug product for samples stored under accelerated and room temperature conditions meet the proposed acceptance criteria. The specifications for individual impurities meet the current USP monograph requirements.
What is the post-approval stability protocol?

In the post-approval stability protocol, the firm commits to place the first three commercial production batches of Methylprednisolone Acetate Injectable Suspension, USP in the marketed container/closure system on stability (25°C ± 2°C/60% ± 5% RH) and tested at intervals of 0, 3, 6, 9, 12, 18, 24 months and 36 months until the desired expiration date is reached. Yearly thereafter, a minimum of one production lot in the marketed container/closure system will be added to the long-term stability program. The stability results will be reported to the Agency in the annual report.

Furthermore, we commit that if any commercial production lot fails to meet the acceptance criteria of stability specifications or falls out of specifications, the Agency shall be informed and appropriate actions shall be taken.

Any significant chemical, physical, or other deterioration which results in the distributed product acquiring non-compliant characteristics will be reported to FDA as a "Field Alert Report" [21 CFR 314.81].

For additional details regarding the post-approval stability protocol refer to Module 3.2.8.2.

Deficiency: In the post-approval stability commitment we note the following statement “any lot that falls out of specifications will be reported to the Agency and appropriate actions taken”. Please clarify what actions will be taken should a lot of the drug product fails the stability specifications.

III. Administrative

   A. Reviewer’s Signature

   B. Endorsement Block

       ChemistName/Date:   RD’Costa, Ph.D./03/28/11
       ChemistryTeamLeaderName/Date:  AMueller PhD./03/28/11
       ProjectManagerName/Date:  Doan Dat, PM, /03/28/11

   C. CC Block

       ANDA
       ANDA DUP
       DIV FILE
       Field Copy
36. CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 201-835  APPLICANT:  Sagent Pharmaceuticals, Inc.

DRUG PRODUCT: Methylprednisolone Acetate Injectable Suspension, USP 40 mg/mL & 80 mg/mL

The deficiencies presented below represent MINOR deficiencies.

A. Deficiencies:

1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 

B. 
Sincerely yours,

{See appended electronic signature page}

Paul Schwartz, Ph.D.
Acting Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research
B. Endorsement Block

ChemistName/Date: RD’Costa, Ph.D./03/28/11
ChemistryTeamLeaderName/Date: AMueller PhD./03/28/11
ProjectManagerName/Date: Doan Dat, PM, /03/28/11

C:\Documents and Settings\dcostar\My Documents\201835.REV01.doc

C. CC Block

ANDA
ANDA DUP
DIV FILE
Field Copy
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

----------------------------

ROSARIO F D COSTA
05/24/2011

----------------------------

DAT T DOAN
06/07/2011

----------------------------

ALBERT J MUELLER
06/08/2011

Reference ID: 2950998